Deep Biotech: disruptive innovation for global sustainability

Maddie Cass.png

Deep Biotech applies the power of biotechnology to address some of humanity's biggest challenges. The life sciences industry has ushered in many ground-breaking innovations in health. In response to the challenge of global warming the same technologies that delivered life-saving therapeutics are being harnessed to disrupt traditional industries and reduce environmental damage.

In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at the BIA, reports on the expansion of the BIA’s activities to serve at the front line of this transformation.


What is Deep Biotech?

The BIA has coined a new term ‘Deep Biotech’ to describe the application of modern biotechnologies to humanity's most profound challenges beyond health, including climate change, pollution and food security. Our growing ability to precisely edit DNA and engineer biology to do new things provides us with an entirely new toolkit to solve problems, just as chemistry did in the 19th Century and physics did in the 20th Century.

As with other instances of deep tech, it is a long-term investment requiring complex scientific research and advanced engineering to reach revolutionary breakthroughs that empower multiple industries to address urgent issues.

This biological innovation is propelling us into what is often referred to as the Fourth Industrial Revolution, the biorevolution. Underpinning this revolution is the continued development of modern, disruptive biotechnologies such as engineering biology, and their purposeful application. Deep Biotech has the potential to unleash the biorevolution and realise UK and global ambitions to create a sustainable bioeconomy. The BIA’s growing Deep Biotech membership is part of that revolution.

Organisations and governments turn to biotech to help them address sustainability challenges

Globally, the impacts of climate change are clear and people, organisations and governments around the world understand the need to make changes to safeguard our future. Innovative biotechnology is seen as a key tool to help us tackle climate change and meet the UN’s Sustainable Development Goals. Multinational companies like Lego are turning to biobased solutions to help green their supply chains.

The UK Government is aware of the scientific and engineering innovations needed to counteract the impacts of global warming. Recent government activity and increased interest in the field of engineering biology, identified as a critical technology, will underpin the transformation towards a more sustainable future.

The Department for Science, Innovation, and Technology (DSIT) recently sought input to a consultation from innovators across business and academic communities to shape coherent UK policy that will support the engineering biology ecosystem, from foundational research through to consumer facing products. The BIA submitted a substantial response to the consultation, building on the already-close relationship we have with DSIT to further the uptake of engineering biology and adoption of Deep Biotech solutions.

Innovative solutions are disrupting the market

UK SMEs are charting the way forward by introducing disruptive biotechnologies to the market. These innovative technologies include:

  • Engineered microbes capable of producing enzymes that efficiently and sustainably break down non-biodegradable materials like plastics. This could revolutionise traditional recycling by transforming plastic waste into a valuable source of new materials, thus driving the circular bioeconomy.
  • Precision breeding, made possible through gene editing, enhances crops with traits such as pest resistance, drought tolerance, and enhanced nutritional content. The recent Genetic Technology Act is a first step towards securing food security with the potential to minimise agriculture's environmental footprint.
  • Cellular agriculture is the practice of cultivating meat, seafood, milk and eggs from cells, removing the environmental burdens of industrial-scale farming. It heralds a more sustainable and ethical future for food production.
  • Biofuels are helping hard-to-decarbonise industries like aviation and shipping meet Net Zero targets. Engineering biology is delivering the next generation of biofuels through genetically engineered crops, or new efficient pathways to transform biowaste into feedstock.
  • Novel textiles and materials can ease our reliance on fossil fuels to make clothing and plastics. Bacteria, fungi and food waste are all being developed as sources to create new fabrics and materials that will challenge the existing industries.
  • Bioremediation restores contaminated environments by harnessing the power of microbes to degrade and detoxify pollutants. These organisms are engineered to breakdown or stabilise contaminants safely, allowing us to clean up polluted natural spaces, restore fertile farmland, and develop abandoned brownfield sites.

BIA will influence, connect, and save for Deep Biotech

Leveraging our extensive experience in supporting the UK's health biotech sector, the BIA is committed to assisting Deep Biotech companies which are at the forefront of applying disruptive biotechnologies beyond healthcare. Working in close consultation with our growing Deep Biotech membership, we are actively developing our activities in this space to empower companies working to tackling some of our world’s most challenging problems, enabling them to start, grow and deliver world-changing innovation in the UK.

We will be publishing a detailed report early next year exploring and characterising this exciting and growing community of companies, and rolling out a range of activities throughout 2024 to support and represent them.

If you are interested to learn more about the BIA’s work in this space, or if you are a member interested in joining our Deep Biotech group, please contact Policy and Public Affairs Manager, Linda Bedenik.

 

More news and updates 

CEO Update - 29 April 2024

Much of the UK will go to the polls this Thursday in the biggest test of public opinion ahead of the UK general election. Ten key metro mayoral contests take place including in Tees Valley, Manchester, the West and East Midlands and London. The results will be announced over the weekend and give a new mandate to key figures in regions of the UK whilst also helping define if we will have a summer or autumn general election.

Harnessing the power of innovation: How the Innovation Map can help your life science company thrive

In this blog, Sam Cruickshank, Programme Manager at BIA, discusses the pivotal role of the recently updated 2024 BIA Innovation Map in empowering life science entrepreneurs to navigate the complexities of the start-up landscape and unlock their ventures' full potential.

RNID shine a spotlight on the hearing therapeutics landscape

In this blog, Melissa Hayman, Hearing Therapeutics Manager at RNID, BIA’s charity partner of the year introduces a blog series to be published over the coming months which will examine the hearing therapeutics landscape.

Continuity and change: Labour’s life science strategy

​​​​Herbie Lambden, Senior Policy and Public Affairs Executive at the BIA, provides a rundown of the BIA Committee Summit, which took place in Westminster on 21 February.

CEO Update - 22 April 2024

The UK's engineering biology scene was out in force at a Number 10 Downing Street reception last week. It was great to celebrate the developments in our community network together with ministers and investors.

Step up and create more inclusive workplaces within the biotech sector

In last year’s Diversity and Inclusion in UK Biotech survey conducted by the BIA, hearing loss emerged as one of the most prevalent disabilities. With Deaf Awareness Week 2024 (6-12 May) fast approaching, the BIA has teamed up with its charity partner, RNID, to offer valuable resources and initiatives for creating more inclusive workplaces across the biotech sector.

Investing in life science – learnings from the first round of investments from Discovery Park Ventures

Launched in May 2022 by thriving life science community Discovery Park, Discovery Park Ventures (DPV) is an investment fund that invests in ambitious and growing life sciences companies, driving disruptive innovation and catalysing economic growth. Initially a £1 million fund, DPV has now expanded to £3 million.

AI in life sciences: future-proofing strategies

In the final piece of the 'AI in life sciences' series, Jenny Yu, Marsh’s Life Sciences industry practice leader and experts from law firm Kennedys emphasize essential steps for life sciences companies to develop and implement a successful AI business strategy. They delve into effective management of outcomes from AI technologies and strategies to mitigate potential risks.

CEO Update - 15 April 2024

In case you missed it last week, post-Brexit border paperwork and inspections have been postponed for the life sciences sector, thanks to BIA work. Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.

CEO Update - 8 April 2024

I don’t always start Newscast with a technical detail – but this one matters and underpins the work of many, many companies in our Association. In short, keep doing your experiments and manufacturing medicines as normal as we work hard to keep your reagents and materials supply chain operating smoothly.

 

More within